Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy

Microbiology and Immunology

Volumn 51, Issue 7, 2007, Pages 685-699

  Yano, Arisa ^a   Komatsu, Toshihiro ^a   Ishibashi, Masahide ^b   Udaka, Keiko ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Osaka University   (Japan)

Author keywords

Adjuvant; Immunotherapy; Peptide; Th1

Indexed keywords

ACELLULAR VACCINE; ARGINYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; GENE PRODUCT; OVALBUMIN; PEPTIDE; PERTUSSIS VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BORDETELLA PERTUSSIS; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENCY; ERYTHROLEUKEMIA; GENE TARGETING; IN VIVO STUDY; MOUSE; NONHUMAN; TH1 CELL; TH2 CELL; TUMOR REJECTION; WHOLE CELL;

BORDETELLA PERTUSSIS; MUS;

EID: 34547118599     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb03957.x     Document Type: Article

References (62)

1. Ausiello, C.M., Lande, R., la Sala, A., Urbani, F., and Cassone, A. 1998. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178: 466-470.
2. Ausiello, C.M., Lande, R., Urbani, F., Di Carlo, B., Stefanelli, P., Salmaso, S., Mastrantonio, P., and Cassone, A. 2000. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181: 1989-1995.
3. Ausiello, C.M., Lande, R., Urbani, F., la Sala, A., Stefanelli, P., Salmaso, S., Mastrantonio, P., and Cassone, A. 1999. Cell-mediatd immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67: 4064-4071.
4. Ausiello, C.M., Urbani, P., la Sala, A., Lande, R., and Cassone, A. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65: 2168-2174.
5. Barnard, A., Mahon, B.P., Watkins, J., Redhead, K., and Mills, K.H.G. 1996. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87: 372-380.
6. Bennett, S.R.M., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F.A.P., and Heath, W.R. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
7. + T cells via antigen cross-presentation. J. Immunol. 176: 7288-7300.
8. Caux, C., Massacrier, C., Vandervliet, B., Dubois, B., Kooten, C.V., Durand, I., and Banchereau, J. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180: 1263-1272.
9. + T cells and monocyte/dendritic cell precursors. Cancer Res. 66: 4943-4950.
10. Dredge, K., Marriott, J.B., Todryk, S.M., and Dalgleish, A.G. 2002. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother. 51: 521-531.
11. + T celldependent tumor eradication in vivo. J. Immunol. 165: 5495-5501.
12. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G.A., and Davis, M.M. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor. Proc. Natl. Acad. Sci. U.S.A. 98: 8809-8814.
13. Fujimoto, C., Yu, C.-R., Shi, G., Vistica, B.P., Wawrousek, E.F., Klinman, D.M., Chan, C.-C., Egwuagu, C.E., and Gery, I. 2006. Pertussis toxin in superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J. Immunol. 177: 6896-6903.
14. Gerloni, M., and Zanetti, M. 2005. CD4 T cells in tumor immunity. Springer Semin. Immun. 27: 37-48.
15. Gillis, S., Smith, K.A., and Watson, J. 1980. Biochemical characterization of lymphocyte regulatory molecules. II. Purification of a class of rat and human lymphokines. J. Immunol. 124: 1954-1962.
16. Haskins, K., Kubo, R., White, J., Pigeon, M., Kappler, J., and Marrack, P. 1983. The major histocompatibility complex-restricted anigen receptor on T cells. J. Exp. Med. 157: 1149-1169.
17. Hogquist, K.A., Jameson, S.C., Heath, W.R., Howard, J.L., Bevan, M.J., and Carbone, F.R. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
18. d. Science 256: 1817-1820.
19. + T lymphocytes. Nature 421: 852-856.
20. Kakugawa, K., Udaka, K., Nakashima, K., Inaba, K., Oka, Y., Sugiyama, H., Tamamura, H., and Yamagishi, H. 2000. Efficient induction of peptide-specific cytotoxic T lymphocytes by LPS-activated spleen cells. Microbiol. Immunol. 44: 123-133.
21. Kanagawa, O., Utsunomiya, Y., Bill, J., Palmer, E., Moore, M.W., and Carbone, F.R. 1991. Conformational difference of T cell antigen receptors revealed by monoclonal antibodies to mouse Vbeta5 T cell receptor for antigen determinants. J. Immunol. 147: 1307-1314.
22. Kennedy, R., and Celis, E. 2006. T helper lymphocytes rescue CTL from activation-induced cell death. J. Immunol. 177: 2862-2872.
23. Lanzavecchia, A. 1998. Licence to kill. Nature 393: 413-414.
24. Lavigne, M., Castro, M., Mateo, N., Deluchi, S., Atzori, C., Piudo, L., Calcagno, M., Brero, M., and Manghi, M. 2002. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen. Microbes Infect. 4: 815-820.
25. Lavigne, M.V., Castro, M., Andino, J., and Manghi, M. 2004. Alternative diphtheria, tetanus and shooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response. Microbes Infect. 6: 481-484.
26. Mahon, B.P., Ryan, M.S., Griffin, F., and Mills, K.H.G. 1996. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis vaccine by promoting induction of Th1 cells. Infect. Immun. 64: 5295-5301.
27. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
28. Marzo, A.L., Lake, R.A., Robinson, B.W.S., and Scott, B. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59: 1071-1079.
29. Mills, K.H.G. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3: 655-677.
30. Moore, M.W., Carbone, F.R., and Bevan, M.J. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
31. Mosolits, S., Ullenhag, G., and Mellstedt, H., 2005. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann. Oncol. 16: 847-862.
32. + T cells can protect APC from CTL-mediated elimination. J. Immunol. 176: 7379-7384.
33. Murphy, E., Shibuya, K., Hosken, N., Openshaw, P., Maino, V., Davis, K., Murphy, K., and O'Garra, A. 1996. Revesibility of T helper 1 and 2 populations is lost after long-term stimulation. J. Exp. Med. 183: 901-913.
34. lo thymocytes in vivo. Science 250: 1720-1723.
35. Nagorsen, D., and Thiel, E. 2006. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. 12: 3064-3069.
36. Nakajima, H., Kawasaki, K., Oka, Y., Tsuboi, A., Kawakami, M., Ikegame, K., Hoshida, Y., Fujiki, F., Nakano, A., Masuda, T., Wu, F., Taniguchi, Y., Yoshihara, S., Elisseeva, O.A., Oji, Y., Ogawa, H., Azuma, I., Kawase, I., Aozasa, K., and Sugiyama, H. 2004. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol. Immunother. 53: 617-624.
37. Nencioni, A., Gruenebach, F., Patrone, F., and Brossart, P. 2004. Anticancer vaccination strategies. Ann. Oncol. 15: 153-160.
38. Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., and Ohta, A. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190: 617-627.
39. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegami, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I., and Sugiyama, H. 2004. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U.S.A. 101: 13885-13890.
40. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T., and Nishimune, Y. 1997. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407: 313-319.
41. + T cells. J. Exp. Med. 198: 569-580.
42. Peterson, A., Harlin, H., and Gajewski, T. 2006. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human Interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21: 2342-2348.
43. Racke, M.K., Hu, W., and Lovett-Racke, A.M. 2005. PTX cruiser: driving autoimmunity via TLR4. Trends Immunol. 26: 289-291.
44. Readhead, K., Watkins, J., Barnard, A., and Mills, K.H.G. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61: 3190-3198.
45. Reynolds, E., Walker, B., Xing, D., Southern, J., Asokanathan, C., Dagg, B., Corbel, M., and Miller, E. 2006. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study. Vaccine 24: 3248-3257.
46. + T-helper and a T-killer cell. Nature 393: 474-478.
47. Roduit, C., Bozzotti, P., Mielcarek, N., Lambert, P.-H., del Giudice, G., Locht, C., and Siegrist, C.A. 2002. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect. Immun. 70: 3521-3528.
48. Romero, P., Cerottini, J.-C., and Speiser, D.E. 2004. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53: 249-255.
49. Rosenberg, S., Yang, J., Schwartzentruber, D., Hwu, P., Marincola, F., Topalian, S., Restifo, N., Dudley, M., Schwarz, S., Spiess, P., Wunderlich, J., Parkhurst, M., Kawakami, Y., Seipp, C., Einhorn, J., and White, D. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
50. Rosenberg, S.A., Yang, J.C., and Restifo, N.P. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
51. Ryan, M., Murphy, G., Ryan, E., Nilsson, L., Shackley, F., Gothefors, L., Oymar, K., Miller, E., Storsaeter, J., and Mills, K.H.G. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93: 1-10.
52. Schoenberger, S.P., Toes, R.E.M., van der Voort, E.I.H., Offringa, R., and Melief, C.J.M. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
53. Shedlock, D.J., and Shen, H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
54. Slingluff, C.L., Petroni, G.R., Yamshchikov, G.V., Barnd, D.L., Eastham, S., Galavotti, H., Patterson, J.W., Deacon, D.H., Hibbitts, S., Teates, D., Neese, P.Y., Grosh, W.W., Chianese-Bullock, K.A., Woodson, E.M.H., Wiernasz, C.J., Merrill, P., Gibson, J., Ross, M., and Engelhard, V.H. 2006. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21: 4016-4026.
55. Speiser, D.E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A.M., Cerottini, J.C., and Romero, P. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
56. Steinaa, L., Rasmussen, P.B., Wegener, A.M., Sonderbye, L., Leach, D.R., Rygaard, J., Mouritsen, S., and Gautam, A.M. 2005. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J. Immunol. 175: 329-334.
57. Stuhler, G., and Walden, P. 1993. Collaboration of helper and cytotoxic T lymphocytes. Eur. J. Immunol. 23: 2279-2286.
58. + T cell reactivity to a model tumor antigen. J. Immunol. 164: 562-565.
59. Thurner, B., Haendle, I., Roeder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Broecker, E.B., Steinman, R.M., Enk, A., Kaempgen, E., and Schuler, G. 1999. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.
60. Toes, R.E.M., Offringa, R., Blom, R.J.J., Melief, C.J.M., and Kast, W.M. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. U.S.A. 93: 7855-7860.
61. Udaka, K., Oka, Y., Tsuboi, A., Elisseeva, O.A., Ogawa, H., Aozasa, K., Kishimoto, T., and Sugiyama, H. 2000. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164: 1873-1880.
62. Weingart, C.L., Keitel, W.A., Edwards, K.M., and Weiss, A.A. 2000. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect. Immun. 68: 7175-7179.